Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer

Abstract

The detection of CK-19 mRNA-positive CTCs in the blood after adjuvant chemotherapy is an independent risk factor indicating the presence of chemotherapy-resistant residual disease.

Gene expression markers in circulating tumor cells may predict bone metastasis and response to hormonal treatment in breast cancer

“…The detection of several markers in the isolated CTCs confirmed that the CTCs originated from the breast and revealed that the majority of the CTCs maintained the properties of breast cancer cells. Previous studies by Ignatiadis et al (19) and Xenidis et al (20) reported that the presence of KRT19 mRNA-positive CTCs prior to the initiation of adjuvant therapy was associated with a shortened disease-free survival and that the presence of KRT19 mRNA-positive CTCs was associated with early clinical relapse and disease-related mortality in 167 node-negative breast cancer patients. In our study, ~50% of the patients exhibited KRT19 overexpression.…”

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer

“…The presence of chemoresistant CTCs or DTCs has been previously described (Braun et al, 2000a;Xenidis et al, 2003Xenidis et al, , 2009) and attributed to the low proliferative capacity of these cells (Pantel et al, 1993;Muller et al, 2005). Therefore, it could be hypothesised that the detection of occult tumour cells after the completion of adjuvant chemotherapy could be used as a surrogate marker for the efficacy of the adjuvant treatment used.…”

“…Several reports have shown that the persistence of occult tumour cells in the bone marrow (Wiedswang et al, 2004;Janni et al, 2005) or peripheral blood (Xenidis et al, 2003(Xenidis et al, , 2009 after adjuvant chemotherapy or during follow-up is associated with an adverse clinical outcome. In this study, the detection of CTCs and/or DTCs after chemotherapy was not associated with increased risk for relapse or death.…”

Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

“…In early BC, initial single-center studies have reported that the detection of peripheral blood CK19 mRNA by RT-PCR after fi coll enrichment of mononuclear cells was an independent prognostic factor for reduced diseasefree survival and overall survival [63,64]. In another study, 13% of 431 early BC patients were CTC-positive according to the AdnaTest®; however, no correlation with clinical outcome was reported [65].…”